Atrioventricular block-induced torsades de pointes with clinical and molecular backgrounds similar to congenital long QT syndrome

Circulation Journal

Volumn 74, Issue 12, 2010, Pages 2562-2571

  Oka, Yuko ^a   Itoh, Hideki ^a   Ding, Wei Guang ^a   Shimizu, Wataru ^b   Makiyama, Takeru ^c   Ohno, Seiko ^c   Nishio, Yukiko ^c   Sakaguchi, Tomoko ^a   Miyamoto, Akashi ^a   Kawamura, Mihoko ^a   Matsuura, Hiroshi ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrioventricular block; Ion channels; Long QT syndrome; Torsades de pointes

Indexed keywords

MEXILETINE; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNE2; POTASSIUM CHANNEL KCNH2; PROPRANOLOL; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; ADULT; AGED; ANIMAL CELL; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DEFIBRILLATOR; ELECTROCARDIOGRAM; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC SCREENING; HEART ELECTROPHYSIOLOGY; HETEROLOGOUS EXPRESSION; HETEROZYGOSITY; HUMAN; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; ONSET AGE; OVARY CELL; PACEMAKER; PHENOTYPE; RECURRENT DISEASE; THERAPY EFFECT; TORSADE DES POINTES; TREATMENT FAILURE; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ATRIOVENTRICULAR BLOCK; CHO CELLS; COHORT STUDIES; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; ION CHANNEL GATING; KCNQ1 POTASSIUM CHANNEL; LONG QT SYNDROME; MALE; MIDDLE AGED; MUTATION, MISSENSE; TORSADES DE POINTES;

EID: 78649711419     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0498     Document Type: Article

References (31)

1. Moss A, Kass R. Long QT syndrome: From channels to cardiac arrhythmias. J Clin Invest 2005; 115: 2018-2024.
2. Shimizu W. Clinical Impact of Genetic Studies in Lethal Inherited Cardiac Arrhythmias. Circ J 2008; 72: 1926-1936.
3. Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S, et al. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol 1992; 69: 628-633.
4. Yoshida H, Horie M, Otani H, Kawashima T, Onishi Y, Sasayama S. Bradycardia-induced long QT syndrome caused by a de novo missense mutation in the S2-S3 inner loop of HERG. Am J Med Genet 2001; 98: 348-352.
5. Lupoglazoff JM, Denjoy I, Villain E, Fressart V, Simon F, Bozio A, et al. Long QT syndrome in neonates: Conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. J Am Coll Cardiol 2004; 43: 826-830.
6. Chevalier P, Bellocq C, Millat G, Piqueras E, Potet F, Schott JJ, et al. Torsades de pointes complicating atrioventricular block: Evidence for a genetic predisposition. Heart Rhythm 2007; 4: 170-174.
7. Nagaoka I, Shimizu W, Itoh H, Yamamoto S, Sakaguchi T, Oka Y, et al. Mutation site dependent variability of cardiac events in Japanese LQT2 form of congenital long-QT syndrome. Circ J 2008; 72: 694-699.
8. Makita N. Phenotypic overlap of cardiac sodium channelopathies. Circ J 2009; 73: 810-817.
9. Ogawa K, Nakamura Y, Terano K, Ando T, Hishitani T, Hoshino K. Isolated non-compaction of the ventricular myocardium associated with long QT syndrome. Circ J 2009; 73: 2169-2172.
10. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353-370.
11. + channel mutation that causes both Brugada and long-QT syndrome phenotypes: A simulation study of mechanism. Circulation 2002; 105: 1208-1213.
12. Itoh H, Sakaguchi T, Ding WG, Watanabe E, Watanabe I, Nishio Y, et al. Latent genetic background and molecular pathogenesis of drug-induced long QT syndrome. Circ Arrhythmia Electrophysiol 2009; 2: 511-523.
13. Tan HL, Bardai A, Shimizu W, Moss AJ, Schulze-Bahr E, Noda T, et al. Genotype-specific onset of arrhythmias in congenital long- QT syndrome. Circulation 2006; 114: 2096-2103.
14. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. KvLQT1 and lsK (minK) proteins associate to form the IKs cardiac potassium current. Nature 1996; 384: 78-80.
15. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al. Coassembly of KvLQT1 and minK (IsK) proteins to form cardiac IKs potassium channel. Nature 1996; 384: 80-83.
16. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channels. Cell 1995; 81: 299-307.
17. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol 1952; 117: 500-544.
18. Newton-Cheh C, Guo CY, Larson MG, Musone SL, Surti A, Camargo AL, et al. Common genetic variant in KCNH2 is associated with QT interval duration: The Framingham Heart Study. Circulation 2007; 116: 1128-1136.
19. Plant LD, Bowers PN, Liu Q, Morgan T, Zhang T, State MW, et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest 2006; 116: 430-435.
20. Nishio Y, Makiyama T, Itoh H, Sakaguchi T, Ohno S, Gong YZ, et al. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol 2009; 54: 812-819.
21. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, et al. Common variants at ten loci influence QT interval duration in the QTGEN study. Nat Genet 2009; 41: 399-406.
22. Pfeufer A, Sanna S, Arking DE, Müller M, Gateva V, Fuchsberger C, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD study. Nat Genet 2009; 41: 407-414.
23. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, et al. A common genetic variant in the NOS1 regulator NOS1AP modulate cardiac repolarization. Nat Genet 2006; 38: 644-651.
24. Crotti L, Monti MC, Insolia R, Peljto A, Goosen A, Brink PA, et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation 2009; 120: 1657-1663.
25. Sakaguchi T, Shimizu W, Itoh H, Noda T, Miyamoto Y, Nagaoka I, et al. Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci 2008; 108: 462-471.
26. Lupoglazoff JM, Cheav T, Baroudi G, Berthet M, Denjoy I, Cauchemez B, et al. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. Circ Res 2001; 89: E16-E21.
27. Chang CC, Acharfi S, Wu MH, Chiang FT, Wang JK, Sung TC, et al. A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia. Cardiovasc Res 2004; 64: 268-278.
28. Miura M, Yamagishi H, Morikawa Y, Matsuoka R. Congenital long QT syndrome and 2:1 atrioventricular block with a mutation of the SCN5A gene. Pediatr Cardiol 2003; 24: 70-72.
29. Nakamura H, Kurokawa J, Bai CX, Asada K, Xu J, Oren RV, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: An in vitro patch-clamp and computational modeling study. Circulation 2007; 116: 2913-2922.
30. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-2597.
31. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 1998; 97: 2237-2244.